Literature DB >> 15504889

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

María Eugenia Pachón-Ibáñez1, Manuel Enrique Jiménez-Mejías, Cristina Pichardo, Ana Cristina Llanos, Jerónimo Pachón.   

Abstract

We determined the in vitro activities of tigecycline and imipenem against 49 isolates of Acinetobacter baumannii, including those resistant to imipenem. The MIC at which 50% of the isolates were inhibited (MIC(50)) and the MIC(90) for tigecycline and imipenem were 2 and 2 mg/liter and 32 and 128 mg/liter, respectively, with 92 and 20%, respectively, of the strains being susceptible. Tigecycline did not show bactericidal activity in the time-kill studies (n = 9 strains). Imipenem showed bactericidal activity against seven out of nine strains. These in vitro results show that tigecycline has good in vitro bacteriostatic activity against A. baumannii, including strains resistant to imipenem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504889      PMCID: PMC525443          DOI: 10.1128/AAC.48.11.4479-4481.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.

Authors:  J M Cisneros; M J Reyes; J Pachón; B Becerril; F J Caballero; J L García-Garmendía; C Ortiz; A R Cobacho
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

3.  Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia.

Authors:  David Martín-Lozano; José Miguel Cisneros; Berta Becerril; Lucila Cuberos; Trinidad Prados; Carlos Ortíz-Leyba; Elías Cañas; Jerónimo Pachón
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

4.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii.

Authors:  X Corbella; M Pujol; J Ayats; M Sendra; C Ardanuy; M A Domínguez; J Liñares; J Ariza; F Gudiol
Journal:  Clin Infect Dis       Date:  1996-08       Impact factor: 9.079

6.  Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.

Authors:  J Y Fagon; J Chastre; A J Hance; P Montravers; A Novara; C Gibert
Journal:  Am J Med       Date:  1993-03       Impact factor: 4.965

7.  In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

Authors:  R T Testa; P J Petersen; N V Jacobus; P E Sum; V J Lee; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit.

Authors:  A Horrevorts; K Bergman; L Kollée; I Breuker; I Tjernberg; L Dijkshoorn
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

9.  Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis.

Authors:  O Lortholary; J Y Fagon; A B Hoi; M A Slama; J Pierre; P Giral; R Rosenzweig; L Gutmann; M Safar; J Acar
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

10.  In vitro activities of tigecycline against the Bacteroides fragilis group.

Authors:  N V Jacobus; L A McDermott; R Ruthazer; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  27 in total

1.  Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.

Authors:  Claudia Lengerke; Michael Haap; Frank Mayer; Lothar Kanz; Martina Kinzig; Ulrike Schumacher; Fritz Sörgel; Reimer Riessen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

4.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

5.  Multidrug resistant acinetobacter infection and their antimicrobial susceptibility pattern in a nigerian tertiary hospital ICU.

Authors:  Victor Ugochukwu Nwadike; Chiedozie Kingsley Ojide; Eziyi Iche Kalu
Journal:  Afr J Infect Dis       Date:  2014

6.  Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic Management.

Authors:  Harmanjit Singh; Pugazhenthan Thangaraj; Amitava Chakrabarti
Journal:  J Clin Diagn Res       Date:  2013-11-10

7.  Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.

Authors:  C Pichardo; M E Pachón-Ibañez; F Docobo-Perez; R López-Rojas; M E Jiménez-Mejías; A Garcia-Curiel; J Pachon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-25       Impact factor: 3.267

8.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.

Authors:  Sonya C Valentine; Deisy Contreras; Stephanie Tan; Lilian J Real; Sheena Chu; H Howard Xu
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.